You just read:

Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Dec 17, 2019, 07:30 ET